Focused Investors LLC Sells 7,200 Shares of Johnson & Johnson (NYSE:JNJ)

Focused Investors LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 0.5% during the 4th quarter, Holdings Channel reports. The firm owned 1,302,800 shares of the company’s stock after selling 7,200 shares during the quarter. Johnson & Johnson makes up approximately 6.6% of Focused Investors LLC’s investment portfolio, making the stock its 4th largest position. Focused Investors LLC’s holdings in Johnson & Johnson were worth $204,201,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Moneta Group Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares in the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $4,609,399,000. Morgan Stanley lifted its stake in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares in the last quarter. Barclays PLC lifted its stake in shares of Johnson & Johnson by 61.0% in the second quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock worth $1,868,351,000 after buying an additional 4,278,512 shares in the last quarter. Finally, Imprint Wealth LLC raised its stake in Johnson & Johnson by 17,087.7% during the second quarter. Imprint Wealth LLC now owns 2,913,480 shares of the company’s stock worth $291,348,000 after purchasing an additional 2,896,529 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Raymond James lifted their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $177.31.

Johnson & Johnson Trading Down 0.9 %

NYSE JNJ opened at $147.52 on Friday. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The stock has a market capitalization of $355.49 billion, a PE ratio of 10.68, a price-to-earnings-growth ratio of 2.50 and a beta of 0.53. The firm has a 50 day moving average of $157.24 and a two-hundred day moving average of $155.98.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the previous year, the business posted $2.35 EPS. The firm’s revenue was down 9.7% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.